The active ingredient in Ozempic® and Wegovy®, Semaglutide, is approaching patent expiry in Canada. This means a new era of exceptionally affordable generic alternatives is coming in early 2026.
🔒 Your information is secure and private
The wait is almost over. In early 2026, lower-cost alternatives to Semaglutide are anticipated to arrive in the market.
Semaglutide is the active ingredient found in brand-name products such as Ozempic® and Wegovy®. Get ready for access to the same effective treatment at a significantly more affordable price.
When key patents and data protection periods expire, the market opens up to competition. This competition is expected to drive the prices of Semaglutide-based GLP-1 medications down dramatically as multiple manufacturers enter the market.
Absolutely. Generic medications are not "knock-offs." They are strictly regulated by the government and must meet the same rigorous standards as the brand-name drugs.
To be authorized for sale, the generic must:
The government and generic manufacturers follow a pricing framework designed to lower costs. Prices are anticipated to fall in stages as multiple generic options are approved and enter the market, increasing competition and maximizing savings for patients.
We are expecting initial availability to begin in early 2026 following the expiry of data protection. Prices will likely fall in stages throughout the year. Please note that availability might be limited or sporadic during the initial launch as manufacturers scale up production to meet high demand.

We offer competitive pricing on all our medications. We'll match if you find a lower price on an identical product at a verified Canadian online pharmacy!
Need help? Call our friendly support team at 1-888-779-2193 or fill out the Contact Form